WallStreetZenWallStreetZen

NASDAQ: MNPR
Monopar Therapeutics Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MNPR

Based on 1 analyst offering 12 month price targets for Monopar Therapeutics.
Min Forecast
$2.00+216.46%
Avg Forecast
$2.00+216.46%
Max Forecast
$2.00+216.46%

Should I buy or sell MNPR stock?

Based on 1 analyst offering ratings for Monopar Therapeutics.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MNPR stock forecasts and price targets.

MNPR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-11

1 of 1

Forecast return on equity

Is MNPR forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.81%

Forecast return on assets

Is MNPR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

MNPR revenue forecast

What is MNPR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$4.3M
Avg 2 year Forecast
$17.0M
Avg 3 year Forecast
$26.4M

MNPR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MNPR$0.63$2.00+216.46%Strong Buy
ABVC$1.04N/AN/A
BNOX$0.96$8.00+733.33%Buy
ERNA$2.14N/AN/A
GRTX$0.19N/AN/A
View Top Biotech Stocks

Monopar Therapeutics Stock Forecast FAQ

Is Monopar Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MNPR) stock is to Strong Buy MNPR stock.

Out of 1 analyst, 1 (100%) are recommending MNPR as a Strong Buy, 0 (0%) are recommending MNPR as a Buy, 0 (0%) are recommending MNPR as a Hold, 0 (0%) are recommending MNPR as a Sell, and 0 (0%) are recommending MNPR as a Strong Sell.

If you're new to stock investing, here's how to buy Monopar Therapeutics stock.

What is MNPR's revenue growth forecast for 2027-2029?

(NASDAQ: MNPR) Monopar Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.

Monopar Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MNPR's revenue for 2027 to be $74,881,628, with the lowest MNPR revenue forecast at $74,881,628, and the highest MNPR revenue forecast at $74,881,628. On average, 1 Wall Street analysts forecast MNPR's revenue for 2028 to be $297,257,373, with the lowest MNPR revenue forecast at $297,257,373, and the highest MNPR revenue forecast at $297,257,373.

In 2029, MNPR is forecast to generate $459,937,274 in revenue, with the lowest revenue forecast at $459,937,274 and the highest revenue forecast at $459,937,274.

What is MNPR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: MNPR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is MNPR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MNPR price target, the average MNPR price target is $2.00, with the highest MNPR stock price forecast at $2.00 and the lowest MNPR stock price forecast at $2.00.

The Wall Street analyst predicted that Monopar Therapeutics's share price could reach $2.00 by Apr 11, 2025. The average Monopar Therapeutics stock price prediction forecasts a potential upside of 216.46% from the current MNPR share price of $0.63.

What is MNPR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: MNPR) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.